Questionnaire for Potential Participants in the AD Pilot Treatment Program using existing FDA Approved Medications
If after filling out the questionnaire, you are selected by our Program Team to participate in the ZN Pilot Treatment Program, you will be contacted by one of our staff members by email and or telephone. Note participants that show signs of being at a higher risk for developing MCI and or early-stage Alzheimer's one of our staff members by email and or telephone. Note participants that show signs of being at a higher risk for developing MCI and or early-stage Alzheimer's after taking the LabCorp or Quest Diagnostics blood test will be eligible to participate in the Pilot Treatment Program. Participants with primary care physicians and or neurologists currently involved in the individual's prognosis will be given a priority at this time due to the involvement of your local physician(s).